aibio
Listings ·
Longeveron does a 1-for-10 reverse split to meet Nasdaq's $1 bid minimum
The split took effect Aug. 26 and cut Class A shares to about 3.04 million. Three weeks later the company reported that its HLHS trial missed its primary endpoint.
LGVN Longeveron Inc.
Longeveron (LGVN) news LGVN reverse split, delisting and offering news
Latest Longeveron news
- Listings
Longeveron tells Nasdaq it lacks audit committee financial expert after director Kender resigns
Longeveron told Nasdaq on March 4, 2026 that it was temporarily out of compliance after director Richard Kender resigned from its audit committee. The company had $19.2 million of cash at December 31, 2024, and its annual report projected that cash would last only into the fourth quarter of 2025.
- Listings
Longeveron gets Nasdaq minimum bid price notice, has until March 23, 2026 to regain compliance
Nasdaq notified Longeveron (LGVN) on September 22, 2025 that its Class A common stock missed the $1.00 minimum bid price. The notice does not cause immediate delisting; a second 180-day period may be available.
- Listings
Longeveron gets Nasdaq notice for trading below the $1.00 minimum bid price
The company has until March 23, 2026 to bring its Class A common stock back above the threshold. The notice has no immediate effect on its listing.
- Financings
Longeveron sets up $10,700,000 at-the-market stock program with H.C. Wainwright
The size is capped by SEC limits for companies with a public float under $75,000,000. Longeveron's stock last sold at $0.77 on September 18, 2025.
What Longeveron does
Longeveron Inc. is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its lead investigational product candidate is laromestrocel, also referred to as Lomecel-B, a proprietary, scalable, allogeneic cellular therapy. The company says laromestrocel has multiple potential modes of action, including pro-vascular, pro-regenerative and anti-inflammatory mechanisms that appear to promote tissue repair and healing, and it describes broad potential applications across a spectrum of disease areas. Since its founding in 2014, the company has focused on building and staffing a current good manufacturing practice manufacturing facility with research and development labs, generating clinical safety and efficacy data, and developing its manufacturing processes. It manufactures its own investigational product candidates for early-phase clinical trials and has initiated enhancements to its Chemistry, Manufacturing and Controls infrastructure to support potential future Biologics License Application submissions. The company states it has no subsidiaries.
| Product or program | What it is | Stage |
|---|---|---|
| Laromestrocel (Lomecel-B) | Proprietary allogeneic cellular therapy with pro-vascular, pro-regenerative and anti-inflammatory mechanisms | Lead investigational product candidate; clinical stage company |
Longeveron annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $12.0 million | $8.1 million |
| Net income (loss) | -$22.7 million | -$16.0 million |
| Cash from operations | -$18.6 million | -$13.9 million |
| Cash and equivalents | $4.7 million | $19.2 million |
| Short-term investments | $0 |
Questions about Longeveron
Did Longeveron do a reverse stock split?
Our latest story on this, dated Aug 24, 2026: "Longeveron does a 1-for-10 reverse split to meet Nasdaq's $1 bid minimum". The story links the filing or release it is based on. Read the story.
Was Longeveron delisted?
Our latest story on this, dated Sep 26, 2025: "Longeveron gets Nasdaq minimum bid price notice, has until March 23, 2026 to regain compliance". The story links the filing or release it is based on. Read the story.
Has Longeveron raised money recently?
Our latest story on this, dated Sep 19, 2025: "Longeveron sets up $10,700,000 at-the-market stock program with H.C. Wainwright". The story links the filing or release it is based on. Read the story.
Has Longeveron received a Nasdaq deficiency notice?
Our latest story on this, dated Sep 26, 2025: "Longeveron gets Nasdaq notice for trading below the $1.00 minimum bid price". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Longeveron?
Longeveron Inc. trades under the ticker LGVN on NASDAQ.
Where is Longeveron listed?
Longeveron Inc. is listed on NASDAQ.
What is the SEC CIK of Longeveron?
The SEC Central Index Key (CIK) for Longeveron Inc. is 1721484. Its filings are on SEC EDGAR.
Which country or territory is Longeveron listed under?
Our directory records Longeveron Inc. under United States.
What does Longeveron do?
Our directory classifies Longeveron Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of Longeveron?
The ISIN recorded for Longeveron Inc. is US54303L3024.
Does aibio.space cover Longeveron?
aibio.space lists Longeveron Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Longeveron incorporated?
SEC records list its state or country of incorporation as DE.
What does Longeveron develop?
Longeveron Inc. is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its lead investigational product candidate is laromestrocel, also referred to as Lomecel-B, a proprietary, scalable, allogeneic cellular therapy.
What is Laromestrocel (Lomecel-B) from Longeveron?
Laromestrocel (Lomecel-B): Proprietary allogeneic cellular therapy with pro-vascular, pro-regenerative and anti-inflammatory mechanisms Stage: Lead investigational product candidate; clinical stage company.
Is Longeveron profitable?
Longeveron Inc. reported a net loss of $22.7 million for the fiscal year ended Dec 31, 2025, and used $18.6 million of cash in operations, per its annual report to the SEC.
Investor discussion: Longeveron
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
- Listings
Reported a reverse stock split. SEC Form 8-K (Items 5.03,7.01,9.01). Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
- Listings
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.03,5.07,9.01). Source
- Listings
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
- Listings
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
- Listings
Reported a reverse stock split. SEC Form 8-K (Items 8.01). Source
- Distress
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
- Listings
Reported a reverse stock split. SEC Form 8-K (Items 1.01,3.02,5.03,8.01,9.01). Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,5.02). Source
- Listings
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
- Financings
Reported a financing. SEC Form 424B5. Source
- Financings
Reported a financing. SEC Form S-1. Source
- Legal
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
- Distress
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Stock chart
SEC filings and registration
- SEC name
- Longeveron Inc.
- CIK
- 1721484
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- US tickers
- LGVN (Nasdaq)
- State or country of incorporation
- DE
- Fiscal year ends
- December 31
- Filer category
- <br>Emerging growth company
- Business address
- 1951 NW 7TH AVENUE, MIAMI, FL, 33136
- Phone
- 305-302-7158
- Former names
- LONGEVERON LLC
Recent filings
Listing details
- Company
- Longeveron Inc.
- Ticker
- LGVN
- Listing
- NASDAQ
- Country or territory
- United States
- Business scope
- Biotechnology
- ISIN
- US54303L3024
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction